Convergence: Toning down pain
Convergence, a GlaxoSmithKline spinout, focused on chronic pain
Convergence Pharmaceuticals Ltd. believes its state-dependent ion channel inhibitors can provide effective analgesia for chronic pain without the side effects associated with tonic ion channel blockers. On the back of a L22.4 million ($35.4 million) series A round, the company plans to start a Phase II trial for its lead molecule this year.
Convergence was spun out of GlaxoSmithKline plc this month after the pharma decided in